BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the appointment of Dr. Trang Ly as Insulet’s Vice President and Medical Director, effective September 12, 2016. In addition, Brittany Bradrick has been appointed Vice President, Strategy and Corporate Development, a newly-created position, effective September 2, 2016.
Dr. Ly is a leading expert in artificial pancreas research and development and brings particular expertise in advancing algorithms for automated insulin delivery. She joins Insulet from Stanford University, where she served as Clinical Assistant Professor in the Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes.
As Vice President, Strategy and Corporate Development, Ms. Bradrick will be responsible for advancing key strategic partnerships, identifying external growth opportunities and leading Insulet’s strategic planning initiatives. She is an accomplished strategy and finance professional with significant life science experience in both corporations and investment banking. She joins Insulet from Abbott Diabetes Care, where she served as Director of Business Development and Alliance Management.
“We are very pleased to welcome Trang and Brittany to our executive team,” said Patrick Sullivan, President and Chief Executive Officer. “Trang is one of the nation’s leading experts in artificial pancreas research and development with years of clinical experience in endocrinology and diabetes in the United States and Australia. Her proven expertise will be a significant asset as we continue to advance our artificial pancreas program and broaden our product development agenda.”
Mr. Sullivan continued, “Brittany brings deep industry knowledge and an exceptional skillset to our leadership team. She will partner with our management team to help Insulet advance our strategic roadmap and maximize the full potential of our external partnerships.”
About Dr. Trang Ly:
Dr. Trang Ly is an expert in artificial pancreas technologies. Most recently, she has held positions at both Stanford University and University of Western Australia, as Clinical Assistant Professor and Research Assistant Professor, respectively. Prior to her time at Stanford, Dr. Ly was a Consultant Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. Dr. Ly holds a Bachelor of Medicine and Surgery, a Diploma of Child Health and a PhD in Pediatrics and Pediatrics Endocrinology from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians with Specialist Qualifications in Pediatrics Endocrinology.
About Brittany Bradrick:
Brittany Bradrick joins Insulet from Abbott Diabetes Care, where she was Director, Business Development and Alliance Management, responsible for leading the division’s global business development efforts, including strategy, acquisitions, dispositions, global partnerships and licensing of intellectual property and technology. Prior to Abbott, Ms. Bradrick advised life science companies for over ten years as an investment banker with Piper Jaffray, Credit Suisse and JP Morgan. She earned a B.S. in Business Administration from the University of Missouri and a MBA from the Johnson Graduate School of Management at Cornell University.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, please visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
All trademarks are the property of their respective owners.